article Open AccessTop 1% cited
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Current Biology · 2007 · Vol. 17(4) · pp. 316–322
Martin Steegmaier(Boehringer Ingelheim (Austria))Matthias Hoffmann(Boehringer Ingelheim (Germany))Anke Baum(Boehringer Ingelheim (Austria))Péter Lénárt(Research Institute of Molecular Pathology)Mark Petronczki(Research Institute of Molecular Pathology)Martin Krššák(Boehringer Ingelheim (Austria))Ulrich Gürtler(Boehringer Ingelheim (Austria))Pilar Garin‐Chesa(Boehringer Ingelheim (Austria))Simone Lieb(Boehringer Ingelheim (Austria))Jens Quant(Boehringer Ingelheim (Austria))Matthias Grauert(Boehringer Ingelheim (Germany))Günther R. Adolf(Boehringer Ingelheim (Austria))Norbert Kraut✉(Boehringer Ingelheim (Austria))Jan‐Michael Peters(Research Institute of Molecular Pathology)Wolfgang J. Rettig(Boehringer Ingelheim (Austria))
Microtubule and mitosis dynamicsCancer-related Molecular PathwaysDNA Repair MechanismsPolo-like kinasePLK1BiologyMitosisKinaseCell cycleCancer researchPrometaphaseCancerCell biology
MeSH terms
Polo-Like Kinase 1AnimalsBody WeightCell CycleDose-Response Relationship, DrugEnzyme InhibitorsFemaleFlow CytometryHeLa CellsHumansImmunohistochemistryMagnetic Resonance ImagingMicroscopy, FluorescenceNeoplasmsProto-Oncogene Proteins
Citations
845
FWCI
16.41
field-weighted impact
References
26
Percentile
100%
vs. same field & year
Citations per year
Cited by
The “Cyclopropyl Fragment” is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules
Journal of Medicinal Chemistry · 2016 · 957 citations
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Cancer Research · 2008 · 1,050 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.